

## 科学研究費助成事業 研究成果報告書

平成 26 年 5 月 30 日現在

機関番号：12601

研究種目：基盤研究(C)

研究期間：2011～2013

課題番号：23591010

研究課題名(和文)膵嚢胞性腫瘍の病態予測における包括的ゲノム解析の応用

研究課題名(英文)Molecular characterization of IPMN using comprehensive genome analysis

研究代表者

多田 稔(TADA, Minoru)

東京大学・医学部附属病院・講師

研究者番号：80302719

交付決定額(研究期間全体)：(直接経費) 4,000,000円、(間接経費) 1,200,000円

研究成果の概要(和文)：25例のIPMNについてKras, Braf, PIK3CAの変異と、p16, smad4の欠失、p53蓄積を検討した。Kras変異はgastric-typeに多く、PIK3CA変異はintestinalの一例に認められた。smad1/5/8のリン酸化がintestinal-typeで多いことを見出し、報告した(J.Gastroenterol. 2012 47(2):203-13)。さらに、膵がん細胞株および臨床検体で増幅を認められた遺伝子のうち、ノックダウンの結果から上皮間葉転換を促進する分子を見出した。この分子のIPMNにおける関与を解析中である。

研究成果の概要(英文)：We characterized the molecular signature of IPMN in this project. 11 gastric, 11 intestinal, one pancreatobiliary, and two oncocytic types were included in this study. We compared the molecular characteristics of two major subtypes, gastric-type and intestinal-type IPMN. Gastric-type showed a higher incidence of KRAS mutations (9/11, 81.8%) compared with intestinal type (3/11, 27.3%). The intestinal type (9/11, 81.8%) demonstrated more frequent SMAD1/5/8 phosphorylation compared with gastric-type IPMN (3/11, 27.3%). In addition, we identified a molecule that accelerated epithelial-mesenchymal transition in pancreas cancer cells. The gene was amplified in pancreas cancer cells and human pancreatic tumors. We now examine the significance of the molecule in IPMN as well as in pancreatic cancers.

研究分野：医歯薬学

科研費の分科・細目：内科系臨床医学・消化器内科学

キーワード：IPMN

## 1. 研究開始当初の背景

膵癌では *Kras* 遺伝子変異がほとんどすべてに検出されることが特徴的である。しかし、膵液レベルの解析では、膵癌のない症例の膵液から *Kras* 遺伝子変異が検出されることがある。当研究室の研究により、膵嚢胞が存在すると膵液中に変異 *Kras* 遺伝子が多く検出されることを明らかとした (Tateishi, Tada et al. Gut 1999)。IPMN (Intraductal Papillary Mucinous Neoplasm) は膵のう胞性腫瘍の一病態で、元来は良性と診断される場合が多い一方、時に悪性化する症例がある。そこで当科では IPMN を含め、膵に嚢胞を有する症例について、画像による経過観察を行ってきた。その結果、膵癌発症が年率 0.9% と高率に認められ、膵嚢胞は膵癌の高危険群であることを突き止めた (Tada M, et al. Clin Gastroenterol Hepatol 2006;4:1265-1270, Tada M. Clin Gastroenterol Hepatol 2007;5:522.)。

その膵嚢胞性腫瘍の一つ IPMN は膵前がん病変である PanIN と類似する病態と考えられるが、PanIN が微小膵管における変化であり基本的に画像診断では捉えられないのに対し、IPMN は嚢胞性病変として捉えられるため、膵癌の早期診断につながる可能性がある。近年、IPMN にも複数のタイプがあることが明らかになり、臨床形態的には主膵管型と分枝型に分類される。また IPMN の組織亜型は 4 種あり、大部分が gastric type と intestinal type に分類される。悪性頻度が高く原則として手術が検討される主膵管型はほとんど intestinal type であることが最近報告され、そのがん化の経過は adenoma-carcinoma sequence に類似すると考えられている。主膵管の intestinal type IPMN の悪性化例はいわゆる近接した部位に生じる IPMN 由来膵がんであることが多いが、一方で分枝膵管型は IPMN と離れた部位に PanIN を介する通常型膵癌が合併する場合がみられる。つまりがん化に至るメカニズムも両者で全く異なる可能性がある。それぞれの特有な分子マーカーがあれば IPMN 病変から浸潤するがん発生に留意すべきなのか、あるいは異所性に生じるがんの確率が高いことに留意すべきか、というような経過予測の上で有効な情報となる可能性もありうる。

癌細胞のゲノムでは、特定の遺伝子領域で増幅や欠失が起こることが知られている。近年、大規模 SNP タイピングを目的として開発された高密度オリゴヌクレオチドアレイが、染色体コピー数変化および LOH を同時に解析できるということがわかった(下図・例)。そこで、当研究室ではこのアレイを用いて膵癌細胞株 25 種類のゲノム異常の網羅的解析を行ってきた。解析の結果、24 のホモ欠失領域と 23 の増幅領域を認め、それぞれ 8 領域

は今回初めて指摘された部位であった。LOH は 9p,18q,17p,8p,13q,6q,3p,6p,22q,9q と 12q において 50% 以上の細胞株に認めた。その後、この新規に増幅および欠失あるいは LOH を認めた領域に関して、膵癌手術検体を用いた解析を行い、細胞株と同様の異常を認めることを確認した (Lin LJ, et al. Oncology. 2008;75(1-2):102-12.)。

## 2. 研究の目的

intestinal type の IPMN に特有の分子マーカーを同定し、早期の治療法決定と発がん予防、また分枝型 IPMN の悪性例の予測にも役立てることを目標とする。

## 3. 研究の方法

IPMN の組織はマイクロダイセクションを活用して選択的に採取し、DNA を抽出する。以前に膵がん検体を用いて同定された遺伝子領域の増幅・欠失といったコピーナンバー異常について定量的 PCR を用いて評価する。またコピーナンバー異常に伴う遺伝子発現変化についても定量的 RTPCR にて評価する。発現異常を認めた遺伝子については膵発がんにおける生物学的役割を検討するために、過剰発現およびノックダウン膵がん細胞を樹立して増殖能、遊走能、浸潤能、腫瘍形成能などについてアッセイを行う。

## 4. 研究成果

25例のIPMNについて *Kras*, *Braf*, *PIK3CA* の変異と、*p16*, *smad4* の欠失、*p53* 蓄積などについて検討を行ってきた。*Kras* 変異は gastric-type に多く、*PIK3CA* 変異が intestinal の一例のみに認められた。その他の分子の異常については亜型によって有意に差を認められなかった。ただし *smad1/5/8* のリン酸化が intestinal-type で有意に認められることを見出し、報告した (J.Gastroenterol. 2012 47(2):203-13)。

さらに、膵がん細胞株およびヒト膵がん検体を用いた検討で、遺伝子増幅を認めた遺伝子のうち、そのノックダウン細胞を用いた実験の結果から膵がん細胞において上皮間葉転換を促進する分子を見出した。現在はこの分子が上皮間葉転換を誘導する分子機構を明らかにし、膵がんのみならず IPMN の生物学的特性における関与について臨床検体での解析も行って検討を続ける。

## 5. 主な発表論文等

(研究代表者、研究分担者及び連携研究者には下線)

〔雑誌論文〕(計 59 件)

Tada M, Nakai Y, Sasaki T, Hamada T, Nagano R, Mohri D, Miyabayashi K, Yamamoto K, Kogure H, Kawakubo K, Ito Y, Yamamoto N, Sasahira N, Hirano K, Ijichi H, Tateishi K, Isayama H, Omata M, Koike K: Recent progress and limitations of chemotherapy for pancreatic and biliary tract cancers. World J Clin Oncol. 2(3):158-63, 2011  
Yashima Y, Tsujino T, Masuzaki R, Nakai Y,

- Hirano K, Tateishi R, Sasahira N, Isayama H, Tada M, Yoshida H, Kawabe T, Omata M: Increased liver elasticity in patients with biliary obstruction. *J Gastroenterol*.46,86-91,2011
- Gonoi W, Akai H, Hagiwara K, Akahane M, Hayashi N, Maeda E, Yoshikawa T, Tada M, Uno K, Ohtsu H, Koike K, Ohtomo K: Pancreas divisum as a predisposing factor for chronic and recurrent idiopathic pancreatitis: initial in vivo survey. *Gut*.60(8),1103-8,2011
- Hamada T, Isayama H, Nakai Y, Togawa O, Kogure H, Kawakubo K, Tsujino T, Sasahira N, Hirano K, Yamamoto N, Arizumi T, Ito Y, Matsubara S, Sasaki T, Yagioka H, Yashima Y, Mohri D, Miyabayashi K, Mizuno S, Nagano R, Takahara N, Toda N, Tada M, Omata M, Koike K: Duodenal invasion is a risk factor for the early dysfunction of biliary metal stents in unresectable pancreatic cancer. *Gastrointest Endosc*.74(3),548-55,2011
- Hirano K, Tada M, Isayama H, Sasahira N, Koike K: Significance of measuring IgG and IgG4 during follow-up of autoimmune pancreatitis. *Pancreas*.40(5),788-91,2011
- Isayama H, Nakai Y, Kawakubo K, Kogure H, Togawa O, Hamada T, Ito Y, Sasaki T, Yamamoto N, Sasahira N, Hirano K, Tsujino T, Tada M, Koike K: Covered metallic stenting for malignant distal biliary obstruction: clinical results according to stent type. *J Hepatobiliary Pancreat Sci*.18(5),673-7,2011
- Isayama H, Nakai Y, Yamamoto K, Sasaki T, Mizuno S, Yagioka H, Yashima Y, Kawakubo K, Kogure H, Arizumi T, Togawa O, Ito Y, Matsubara S, Yamamoto N, Sasahira N, Hirano K, Tsujino T, Tada M, Omata M, Koike K: Gemcitabine and oxaliplatin combination chemotherapy for patients with refractory pancreatic cancer. *Oncology*.80(1-2),97-101,2011
- Kawakubo K, Isayama H, Nakai Y, Togawa O, Sasahira N, Kogure H, Sasaki T, Matsubara S, Yamamoto N, Hirano K, Tsujino T, Toda N, Tada M, Omata M, Koike K: Efficacy and safety of covered self-expandable metal stents for management of distal malignant biliary obstruction due to lymph node metastases. *Surg Endosc*.25(9),3094-100,2011
- Kawakubo K, Isayama H, Sasahira N, Nakai Y, Kogure H, Sasaki T, Hirano K, Tada M, Koike K: Endoscopic transpapillary gallbladder drainage with replacement of a covered self-expandable metal stent. *World J Gastrointest Endosc*.3(2),46-8,2011
- Kawakubo K, Tada M, Isayama H, Sasahira N, Nakai Y, Yamamoto K, Kogure H, Sasaki T, Hirano K, Ijichi H, Tateishi K, Yoshida H, Koike K: Incidence of extrapancreatic malignancies in patients with intraductal papillary mucinous neoplasms of the pancreas. *Gut*.60(9),1249-53,2011
- Kogure H, Isayama H, Kawakubo K, Sasaki T, Yamamoto N, Hirano K, Sasahira N, Tsujino T, Tada M, Koike K: Endoscopic bilateral metallic stenting for malignant hilar obstruction using newly designed stents. *J Hepatobiliary Pancreat Sci*.18(5),653-7,2011
- Kogure H, Isayama H, Nakai Y, Tsujino T, Ito Y, Yamamoto K, Mizuno S, Yagioka H, Kawakubo K, Sasaki T, Hirano K, Sasahira N, Tada M, Omata M, Koike K: Newly designed large cell Niti-S stent for malignant hilar biliary obstruction: a pilot study. *Surg Endosc*.25(2),463-7,2011
- Kogure H, Tsujino T, Yamamoto K, Mizuno S, Yashima Y, Yagioka H, Kawakubo K, Sasaki T, Nakai Y, Hirano K, Sasahira N, Isayama H, Tada M, Kawabe T, Omata M, Harada S, Ota Y, Koike K: Fever-based antibiotic therapy for acute cholangitis following successful endoscopic biliary drainage. *J Gastroenterol*.46(12),1411-7,2011
- Nakai Y, Ikeda H, Nakamura K, Kume Y, Fujishiro M, Sasahira N, Hirano K, Isayama H, Tada M, Kawabe T, Komatsu Y, Omata M, Aoki J, Koike K, Yatomi Y: Specific increase in serum autotaxin activity in patients with pancreatic cancer. *Clin Biochem*.44(8-9):576-81,2011
- Nakai Y, Isayama H, Sasaki T, Sasahira N, Tsujino T, Kogure H, Yagioka H, Yashima Y, Togawa O, Arizumi T, Matsubara S, Hirano K, Tada M, Omata M, Koike K: Comorbidity, not age, is prognostic in patients with advanced pancreatic cancer receiving gemcitabine-based chemotherapy. *Crit Rev Oncol Hematol*.78(3),252-9,2011
- Nakai Y, Isayama H, Togawa O, Kogure H, Tsujino T, Yagioka H, Yashima Y, Sasaki T, Ito Y, Matsubara S, Hirano K, Sasahira N, Toda N, Tada M, Kawabe T, Omata M, Koike K: New method of covered wallstents for distal malignant biliary obstruction to reduce early stent-related complications based on characteristics. *Dig Endosc*.23(1),49-55,2011
- Nakai Y, Isayama H, Tsujino T, Sasahira N, Hirano K, Kogure H, Sasaki T, Kawakubo K, Yagioka H, Yashima Y, Mizuno S, Yamamoto K, Arizumi T, Togawa O, Matsubara S, Yamamoto N, Tada M, Omata M, Koike K: Impact of introduction of wire-guided cannulation in therapeutic biliary endoscopic retrograde cholangiopancreatography. *J Gastroenterol Hepatol*.26(10),1552-8,2011
- Sasaki T, Isayama H, Nakai Y, Mizuno S, Yamamoto K, Yagioka H, Yashima Y, Kawakubo K, Kogure H, Togawa O, Matsubara S, Sasahira N, Hirano K, Tsujino T, Tada M, Omata M, Koike K: Feasibility study of gemcitabine and cisplatin combination chemotherapy for patients with refractory biliary tract cancer. *Invest New Drugs*. 29(6),1488-93,2011
- Sasaki T, Isayama H, Nakai Y, Togawa O, Kogure H, Ito Y, Yamamoto K, Mizuno S, Yagioka H, Yashima Y, Kawakubo K, Arizumi T, Matsubara S, Sasahira N, Hirano K, Tsujino T, Toda N, Tada M, Omata M, Koike K: Prognostic factors in patients with advanced biliary tract

- cancer receiving chemotherapy. *Cancer Chemother Pharmacol.*67(4),847-53,2011
- Yagioka H, Hirano K, Isayama H, Tsujino T, Sasahira N, Nagano R, Hamada T, Miyabayashi K, Ito Y, Mohri D, Kawakubo K, Kogure H, Sasaki T, Tada M, Koike K: Clinical significance of bile cytology via an endoscopic nasobiliary drainage tube for pathological diagnosis of malignant biliary strictures. *J Hepatobiliary Pancreat Sci.*18(2),211-5,2011
- Yashima Y, Tsujino T, Masuzaki R, Nakai Y, Hirano K, Tateishi R, Sasahira N, Isayama H, Tada M, Yoshida H, Kawabe T, Omata M: Increased liver elasticity in patients with biliary obstruction. *J Gastroenterol.*46(1),86-91,2011
- Kawakubo K, Tada M, Koike K: Intraductal papillary mucinous neoplasm was associated with pancreatic carcinogenesis, but not with systemic carcinogenesis. *Surgery* 152(1),141-2,2012
- Gonoi W, Akai H, Hagiwara K, Akahane M, Hayashi N, Maeda E, Yoshikawa T, Kiryu S, Tada M, Uno K, Ohtsu H, Okura N, Koike K, Ohtomo K: Meandering main pancreatic duct as a relevant factor to the onset of idiopathic recurrent acute pancreatitis. *PLoS One.*7(5),e37652,2012
- Hamada T, Nakai Y, Isayama H, Togawa O, Kogure H, Kawakubo K, Tsujino T, Sasahira N, Hirano K, Yamamoto N, Ito Y, Sasaki T, Mizuno S, Toda N, Tada M, Koike K: One- and two-step self-expandable metal stent placement for distal malignant biliary obstruction: a propensity analysis. *J Gastroenterol.*47(11),1248-56,2012
- Hirano K, Isogawa A, Tada M, Isayama H, Takahara N, Miyabayashi K, Mizuno S, Mohri D, Kawakubo K, Sasaki T, Kogure H, Yamamoto N, Sasahira N, Toda N, Nagano R, Yagioka H, Yashima Y, Hamada T, Ito Y, Koike K: Long-term prognosis of autoimmune pancreatitis in terms of glucose tolerance. *Pancreas.*41(5),691-5,2012
- Hirano K, Matsubara S, Tada M, Isayama H, Sasahira N, Koike K: Autoimmune pancreatitis with low serum immunoglobulin G4 level associated with annular pancreas. *Pancreas.*41(5),811-3,2012
- Hirano K, Tada M, Mizuno S, Isayama H, Takahara N, Nagano R, Hamada T, Miyabayashi K, Ito Y, Mohri D, Kawakubo K, Sasaki T, Kogure H, Yamamoto N, Sasahira N, Yamashiki N, Sugawara Y, Kokudo N, Toda N, Koike K: Lower incidence of biliary carcinoma in patients with primary sclerosing cholangitis and high serum levels of immunoglobulin E. *Clin Gastroenterol Hepatol.*10(1),79-83,2012
- Isayama H, Sasaki T, Nakai Y, Togawa O, Kogure H, Sasahira N, Yashima Y, Kawakubo K, Ito Y, Hirano K, Tsujino T, Toda N, Tada M, Omata M, Koike K: Management of malignant gastric outlet obstruction with a modified triple-layer covered metal stent. *Gastrointest Endosc.*75(4),757-63,2012
- Kawakubo K, Isayama H, Nakai Y, Sasahira N, Kogure H, Sasaki T, Hirano K, Tada M, Koike K: Simultaneous duodenal metal stent placement and EUS-guided choledochoduodenostomy for unresectable pancreatic cancer. *Gut Liver.*6(3),399-402,2012
- Kawakubo K, Isayama H, Nakai Y, Togawa O, Sasahira N, Kogure H, Sasaki T, Matsubara S, Yamamoto N, Hirano K, Tsujino T, Toda N, Tada M, Omata M, Koike K: Risk factors for pancreatitis following transpapillary self-expandable metal stent placement. *Surg Endosc.*26(3),771-6,2012
- Kawakubo K, Isayama H, Sasahira N, Kogure H, Miyabayashi K, Hirano K, Tada M, Koike K: Mucosal hyperplasia in an uncovered portion of partially covered metal stent. *World J Gastrointest Endosc.*4(9),432-3,2012
- Kawakubo K, Isayama H, Sasahira N, Kogure H, Takahara N, Miyabayashi K, Mizuno S, Yamamoto K, Mohri D, Sasaki T, Yamamoto N, Nakai Y, Hirano K, Tada M, Koike K: Clinical utility of single-operator cholangiopancreatography using a SpyGlass probe through an endoscopic retrograde cholangiopancreatography catheter. *J Gastroenterol Hepatol.*27(8),1371-6,2012
- Kawakubo K, Isayama H, Tsujino T, Nakai Y, Sasahira N, Kogure H, Hamada T, Nagano R, Miyabayashi K, Yamamoto K, Mohri D, Sasaki T, Ito Y, Yamamoto N, Hirano K, Tada M, Koike K: Endoscopic removal of a spontaneously fractured biliary uncovered self-expandable metal stent. *Dig Endosc.*24(3),182-4,2012
- Maeda E, Akahane M, Yoshioka N, Takao H, Matsuda I, Kamiya K, Hirano K, Tada M, Ohtsu H, Fukushima N, Ohtomo K: Comparison of CT findings of biliary tract changes with autoimmune pancreatitis and extrahepatic bile duct cholangiocarcinoma. *Jpn J Radiol.*30(3),227-34,2012
- Matsubara S, Tada M, Akahane M, Yagioka H, Kogure H, Sasaki T, Arizumi T, Togawa O, Nakai Y, Sasahira N, Hirano K, Tsujino T, Isayama H, Toda N, Kawabe T, Ohtomo K, Omata M: Incidental pancreatic cysts found by magnetic resonance imaging and their relationship with pancreatic cancer. *Pancreas.*41(8),1241-6,2012
- Mohri D, Asaoka Y, Ijichi H, Miyabayashi K, Kudo Y, Seto M, Ohta M, Tada M, Tanaka Y, Ikenoue T, Tateishi K, Isayama H, Kanai F, Fukushima N, Tada M, Kawabe T, Omata M, Koike K: Different subtypes of intraductal papillary mucinous neoplasm in the pancreas have distinct pathways to pancreatic cancer progression. *J Gastroenterol.*47(2),203-13,2012
- Nakai Y, Isayama H, Ijichi H, Sasaki T, Kogure H, Yagioka H, Miyabayashi K, Mizuno S, Yamamoto K, Mouri D, Kawakubo K, Yamamoto N, Hirano K, Sasahira N, Tateishi K, Tada M, Koike K: Phase I trial of gemcitabine and candesartan combination therapy in normotensive patients with advanced pancreatic cancer:

- GECA1. *Cancer Sci*,103(8),1489-92,2012.
- Nakai Y, Isayama H, Sasaki T, Sasahira N, Tsujino T, Toda N, Kogure H, Matsubara S, Ito Y, Togawa O, Arizumi T, Hirano K, Tada M, Omata M, Koike K: A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study. *Br J Cancer*.106(12),1934-9,2012
- Nakai Y, Ishigami H, Isayama H, Sasaki T, Kawakubo K, Kogure H, Emoto S, Yamaguchi H, Kitayama J, Yamamoto N, Sasahira N, Hirano K, Tada M, Koike K: Role of intervention for biliary and gastric/intestinal obstruction in gastric cancer with peritoneal metastasis. *J Gastroenterol Hepatol*.27(12),1796-800,2012
- Sasaki T, Isayama H, Nakai Y, Mizuno S, Yamamoto K, Yagioka H, Yashima Y, Kawakubo K, Kogure H, Togawa O, Matsubara S, Ito Y, Sasahira N, Hirano K, Tsujino T, Toda N, Tada M, Omata M, Koike K: Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine. *Invest New Drugs*.30(2),708-13,2012
- Sasaki T, Isayama H, Nakai Y, Togawa O, Kogure H, Kawakubo K, Mizuno S, Yashima Y, Ito Y, Yamamoto N, Sasahira N, Hirano K, Tsujino T, Toda N, Tada M, Omata M, Koike K: Predictive factors of solid food intake in patients with malignant gastric outlet obstruction receiving self-expandable metallic stents for palliation. *Dig Endosc*.24(4),226-30,2012
- Takahara N, Isayama H, Sasaki T, Tsujino T, Toda N, Sasahira N, Mizuno S, Kawakubo K, Kogure H, Yamamoto N, Nakai Y, Hirano K, Tada M, Omata M, Koike K: Endoscopic papillary balloon dilation for bile duct stones in patients on hemodialysis. *J Gastroenterol*.47(8),918-23,2012
- Yashima Y, Sasahira N, Isayama H, Kogure H, Ikeda H, Hirano K, Mizuno S, Yagioka H, Kawakubo K, Sasaki T, Nakai Y, Tada M, Yoshida H, Omata M, Koike K: Acoustic radiation force impulse elastography for noninvasive assessment of chronic pancreatitis. *J Gastroenterol*.47(4),427-32,2012
- Nakai Y, Isayama H, Sasaki T, Mizuno S, Sasahira N, Kogure H, Kawakubo K, Yamamoto N, Hirano K, Ijichi H, Tateishi K, Tada M, Koike K: Clinical outcomes of chemotherapy for diabetic and nondiabetic patients with pancreatic cancer: better prognosis with statin use in diabetic patients. *Pancreas*.42(2),202-8,2013
- Takahara N, Nakai Y, Isayama H, Sasaki T, Satoh Y, Takai D, Hamada T, Uchino R, Mizuno S, Miyabayashi K, Mohri D, Kawakubo K, Kogure H, Yamamoto N, Sasahira N, Hirano K, Ijichi H, Tada M, Yatomi Y, Koike K: Uridine diphosphate glucuronosyl transferase 1 family polypeptide A1 gene (UGT1A1) polymorphisms are associated with toxicity and efficacy in irinotecan monotherapy for refractory pancreatic cancer. *Cancer Chemother Pharmacol*. 71(1),85-92,2013
- Hamada T, Nakai Y, Isayama H, Sasaki T, Kogure H, Kawakubo K, Sasahira N, Yamamoto N, Togawa O, Mizuno S, Ito Y, Hirano K, Toda N, Tada M, Koike K: Duodenal metal stent placement is a risk factor for biliary metal stent dysfunction: an analysis using a time-dependent covariate. *Surg Endosc*. 27(4),1243-8,2013
- Tsujino T, Isayama H, Nakai Y, Ito Y, Togawa O, Toda N, Arizumi T, Kogure H, Yamamoto K, Mizuno S, Yashima Y, Yagioka H, Sasaki T, Matsubara S, Yamamoto N, Hirano K, Sasahira N, Tada M, Koike K: The results of the Tokyo trial of prevention of post-ERCP pancreatitis with risperidone (Tokyo P3R): a multicenter, randomized, phase II, non-placebo-controlled trial. *J Gastroenterol*. 48(8),982-8,2013
- Gonoi W, Akahane M, Tada M, Ohtomo K: False pancreas divisum: a complication of post-endoscopic retrograde pancreatography pancreatitis. *Jpn J Radiol*. 31(2),148-51,2013
- Hirano K, Tada M, Isayama H, Watanabe T, Saito T, Uchino R, Hamada T, Miyabayashi K, Mizuno S, Mohri D, Sasaki T, Kogure H, Yamamoto N, Sasahira N, Toda N, Takahara N, Yagioka H, Akiyama D, Ito Y, Koike K: High alcohol consumption increases the risk of pancreatic stone formation and pancreatic atrophy in autoimmune pancreatitis. *Pancreas*. 42(3),502-5,2013
- Sasaki T, Isayama H, Maetani I, Nakai Y, Kogure H, Kawakubo K, Mizuno S, Yagioka H, Matsubara S, Ito Y, Yamamoto N, Sasahira N, Hirano K, Tsujino T, Toda N, Tada M, Koike K: Japanese multicenter estimation of WallFlex duodenal stent for unresectable malignant gastric outlet obstruction. *Dig Endosc*. 25(1),1-6,2013
- Kawakubo K, Isayama H, Mizuno S, Hirano K, Yamamoto N, Takahara N, Miyabayashi K, Mohri D, Sasaki T, Kogure H, Sasahira N, Tada M, Koike K: One-step, simultaneous triple endoscopic nasobiliary drainage for hilar biliary stricture. *Dig Endosc*. 25(1), 76-9,2013
- Kawakubo K, Tada M, Isayama H, Sasahira N, Nakai Y, Takahara N, Miyabayashi K, Yamamoto K, Mizuno S, Mohri D, Kogure H, Sasaki T, Yamamoto N, Tateishi R, Hirano K, Ijichi H, Tateishi K, Koike K: Risk for mortality from causes other than pancreatic cancer in patients with intraductal papillary mucinous neoplasm of the pancreas. *Pancreas*. 42(4),687-91,2013
- Yamamoto N, Isayama H, Kawakubo K, Sasahira N, Hamada T, Ito Y, Takahara N, Uchino R, Miyabayashi K, Mizuno S, Kogure H, Sasaki T, Nakai Y, Kuwatani M, Hirano K, Tada M, Koike K: Preliminary report on a new, fully covered, metal stent designed for the treatment of pancreatic fluid collections. *Gastrointest Endosc*. 77(5),809-14,2012
- Nakai Y, Isayama H, Ijichi H, Sasaki T, Takahara N, Ito Y, Matsubara S, Uchino R, Yagioka H, Arizumi T, Hamada T, Miyabayashi K, Mizuno S, Yamamoto K, Kogure H, Yamamoto N, Hirano K,

Sasahira N, Tateishi K, Tada M, Koike K: A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2. Invest New Drugs. 31(5),1294-9,2013

Mizuno S, Nakai Y, Isayama H, Takahara N, Miyabayashi K, Yamamoto K, Kawakubo K, Mohri D, Kogure H, Sasaki T, Yamamoto N, Sasahira N, Hirano K, Tsujino T, Ijichi H, Tateishi K, Tada M, Koike K: Diabetes is a useful diagnostic clue to improve the prognosis of pancreatic cancer. Pancreatology. 13(3),285-9,2013

Sasaki T, Isayama H, Nakai Y, Takahara N, Satoh Y, Takai D, Kogure H, Yamamoto N, Hirano K, Tada M, Yatomi Y, Koike K: A pilot study of salvage irinotecan monotherapy for advanced biliary tract cancer. Anticancer Res. 233(6),2619-22,2013

Uchino R, Isayama H, Tsujino T, Sasahira N, Ito Y, Matsubara S, Takahara N, Arizumi T, Toda N, Mohri D, Togawa O, Yagioka H, Yanagihara Y, Nakajima K, Akiyama D, Hamada T, Miyabayashi K, Mizuno S, Kawakubo K, Kogure H, Sasaki T, Yamamoto N, Nakai Y, Hirano K, Tada M, Koike K: Results of the Tokyo trial of prevention of post-ERCP pancreatitis with risperidone-2: a multicenter, randomized, placebo-controlled, double-blind clinical trial. Gastrointest Endosc. 78(6),842-50,2013

Takahara N, Isayama H, Nakai Y, Sasaki T, Hamada T, Uchino R, Mizuno S, Miyabayashi K, Kogure H, Yamamoto N, Sasahira N, Hirano K, Ijichi H, Tateishi K, Tada M, Koike K: A retrospective study of S-1 and oxaliplatin combination chemotherapy in patients with refractory pancreatic cancer. Cancer Chemother Pharmacol. 72(5),985-90,2013

Sasaki T, Isayama H, Nakai Y, Takahara N, Akiyama D, Yagioka H, Kogure H, Matsubara S, Ito Y, Yamamoto N, Sasahira N, Hirano K, Toda N, Tada M, Koike K: A retrospective study of gemcitabine and cisplatin combination therapy as second-line treatment for advanced biliary tract cancer. Chemotherapy. 59(2),106-11,2013

Hamada T, Nakai Y, Isayama H, Saito K, Kogure H, Sasaki T, Yamamoto N, Hirano K, Tada M, Koike K: Trimming a covered metal stent during hepaticogastrostomy by using argon plasma coagulation. Gastrointest Endosc. 78(6),817,2013

Nakai Y, Isayama H, Sasaki T, Takahara N, Hamada T, Uchino R, Mizuno S, Miyabayashi K, Yamamoto K, Mohri D, Kogure H, Yamamoto N, Hirano K, Ijichi H, Tateishi K, Tada M, Koike K: A retrospective analysis of early CA19-9 change in salvage chemotherapy for refractory pancreatic cancer. Cancer Chemother Pharmacol. 72(6),1291-7,2013

Isayama H, Kawakubo K, Nakai Y, Inoue K, Gon C, Matsubara S, Kogure H, Ito Y, Tsujino T, Mizuno S, Hamada T, Uchino R, Miyabayashi K, Yamamoto K, Sasaki T, Yamamoto N, Hirano K, Sasahira N, Tada M, Koike K: A novel, fully

covered laser-cut nitinol stent with antimigration properties for nonresectable distal malignant biliary obstruction: a multicenter feasibility study. Gut Liver. 7(6),725-30,2013

Mizuno S, Nakai Y, Isayama H, Yanai A, Takahara N, Miyabayashi K, Yamamoto K, Kawakubo K, Mohri D, Kogure H, Sasaki T, Yamamoto N, Sasahira N, Hirano K, Tsujino T, Ijichi H, Tateishi K, Akanuma M, Tada M, Koike K: Risk factors and early signs of pancreatic cancer in diabetes: screening strategy based on diabetes onset age. J Gastroenterol. 48(2),238-46,2013

〔学会発表〕(計5件)

川久保和道, 多田稔, 小池和彦: IPMN 経過観察における膵発癌リスクファクターの検討. 第98回日本消化器病学会総会ワークショップ. 東京, 2012

川久保和道, 多田稔, 小池和彦: 分枝型 IPMN 経過観察中に発生した通常型膵癌診断の現状. 第83回日本消化器内視鏡病学会総会ワークショップ. 東京, 2012

川久保和道, 多田稔, 伊佐山浩通, 笹平直樹, 平野賢二, 高原楠昊, 宮林弘至, 水野卓, 毛利大, 佐々木隆, 木暮宏史, 山本夏代, 小池和彦: IPMN における膵発癌危険因子の検討. 第43回日本膵臓学会シンポジウム. 山形, 2012

Kawakubo K, Tada M, Isayama H, Koike K: Risk of mortality other than pancreatic cancer in patients with intraductal papillary mucinous neoplasm of the pancreas. United European Gastroenterology Week 2012. Amsterdam, 2012

高木馨, 多田稔, 川畑修平, 斎藤友隆, 渡邊健雄, 内野里枝, 濱田毅, 水野卓, 宮林弘至, 木暮宏史, 佐々木隆, 山本夏代, 中井陽介, 平野賢二, 伊佐山浩通, 小池和彦: 膵嚢胞および10mm未満のIPMNの発癌リスクの検討. 第44回日本膵臓学会大会特別企画ディベート. 仙台, 2013

## 6. 研究組織

### (1) 研究代表者

多田 稔 (TADA Minoru)

東京大学・医学部附属病院・講師

研究者番号: 80302719

### (2) 研究分担者

立石 敬介 (TATEISHI Keisuke)

東京大学・医学部附属病院・講師

研究者番号: 20396948

毛利 大 (MOHRI Dai)

東京大学・医学部附属病院・特任臨床医

研究者番号: 20582513